Omnitram Pharmacokinetic Study In Healthy Volunteers

• ClinicalTrials.gov Identifier: NCT02205554
• Recruitment Status: Completed
• First Posted: July 31, 2014
• Last Update Posted: October 15, 2014
• Sponsor: Syntrix Biosystems, Inc.
• Collaborator: National Institute on Drug Abuse (NIDA)
• Information provided by (Responsible Party): Syntrix Biosystems, Inc.

Study Description

Brief Summary:

The purpose of this study is to compare the safety, pharmacokinetic properties (the absorption, distribution and excretion), and analgesic activity of Omnitram (10 mg tablets), Tramadol (Ultram, 50 mg tablet) following oral administration of 9 doses healthy subjects.

Condition or disease	Intervention/treatment	Phase
Pain	Drug: Omnitram; Drug: Tramadol; Drug: Placebo	Phase 1

Detailed Description:

A Phase 1, single-center, randomized, double-blind, placebo-controlled, three-period cross-over study to compare the safety, steady-state oral pharmacokinetics, and clinical activity of overencapsulated: 20 mg Omnitram (2x10 mg tablets), 50 mg Tramadol (1x50 mg Ultram tablet), and placebo.

Forty male subjects in normal health, 21 to 55 years of age, will be randomized to three parallel arms (N=~13 each) to ingest a total of 9 doses of Omnitram, Tramadol, or placebo in a first treatment segment (one dose every 6 hours). Around the 9th dose blood samples are collected to quantify plasma Tramadol and Metabolite 1 (M1) enantiomers. After the 9th dose, pain tolerance is assessed with a cold pressor test (ice cold water immersion). After the 7th dose abuse liability measures and pupil diameter will be assessed. Subjects will washout for 7 days after the first treatment segment and second treatment segment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 43 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Triple Cross-Over Study Investigating The Safety, Oral Steady-State Pharmacokinetics, And Clinical Activity Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects
• Study Start Date: August 2014
• Actual Primary Completion Date: October 2014
• Actual Study Completion Date: October 2014

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Omnitram-Tramadol-Placebo; Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses.	Drug: Omnitram; Nine 20 mg doses administered every 6 hours; Drug: Tramadol; Nine 50 mg doses administered every 6 hours.; Drug: Placebo; Nine doses administered every 6 hours.
Active Comparator: Tramadol-Placebo-Omnitram; Tramadol 20 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses.	Drug: Omnitram; Nine 20 mg doses administered every 6 hours; Drug: Tramadol; Nine 50 mg doses administered every 6 hours.; Drug: Placebo; Nine doses administered every 6 hours.
Active Comparator: Placebo-Omnitram-Tramadol; Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses.	Drug: Omnitram; Nine 20 mg doses administered every 6 hours; Drug: Tramadol; Nine 50 mg doses administered every 6 hours.; Drug: Placebo; Nine doses administered every 6 hours.

Outcome Measures

Primary Outcome Measures :

1. Omnitram and Tramadol Steady State Maximum and Minimum Concentrations [ Time Frame: 0.0, 1.0, 1.5, 2.0, 2.5, and 4.0 hours after the 9th dose of Omnitram and Tramadol. ]
2. Adverse events [ Time Frame: 29 days ]

Secondary Outcome Measures :

1. Cold Water Induced-Pain Reported On a 0 to 10 Scale [ Time Frame: On Study Day 2, Study Day 12, and Study Day 22, after the 9th dose of Omnitram, Tramadol, and placebo. ]
   Subject immerses a hand in cold water for a maximum of 3 minutes and reports level of pain.
2. Abuse Liability Assessed With Visual Analogue Scales [ Time Frame: On Study Day 1, Study Day 11, and Study Day 21, after the 7th dose of Omnitram, Tramadol, and placebo. ]
   Subjects read a question and respond by placing a mark on a visual analogue scale.

Other Outcome Measures:

1. Pupil Size [ Time Frame: On Study Day 1, Study Day 11, and Study Day 21, after the 7th dose of Omnitram, Tramadol, and placebo. ]
   A pupilometer is used to measure eye pupil size.

Eligibility Criteria

• Ages Eligible for Study: 21 Years to 55 Years (Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Healthy male with normal vital signs: systolic blood pressure > 90 mm Hg and < 140 mm Hg; diastolic blood pressure > 50 mm Hg and < 90 mm Hg; pulse 50 to 100 beats per minute; respiratory rate 12 to 20 breathes per minute
2. Between the ages of 21 and 55 years of age
3. Able and willing to give informed consent
4. Able to comply with all study procedures

5. Have adequate hematologic function as evidenced by the following screening results:

   • White Blood Cell (WBC) >3,500/mm3 and < 12,000/mm3;
   • Platelet Count > 150,000/mm3 and < 540,000/mm3;
   • Hemoglobin > 12.5 gm/dL and < 20.5 gm/dL.

   Have adequate liver function as evidenced by the following screening results:

   • Aspartate transaminase (AST) ≤ 60 IU/L;
   • Alanine transaminase (ALT) ≤ 83 IU;
   • Alkaline Phosphatase ≤ 150 IU/L;
   • Total Bilirubin ≤ 1.2 mg/dL;
   • Prothrombin Time (PT) < 1.2 upper limit of normal (ULN); Partial Thromboplastin Time (PTT) < 1.2 ULN.
6. Electrocardiogram (ECG) within normal limits as determined by the PI

7. Have adequate renal function as evidenced by the following screening result:

   Glomerular filtration rate (GFR) calculated by Cockcroft-Gault formula >60 ml/min.

   Urinalysis demonstrating < +1 glucose, +1 ketones, and +1 protein

8. Negative urine test for substances of abuse, including opiates, per clinical research unit (CRU) standards
9. Negative serology tests for HIV, hepatitis B surface antigen and hepatitis C virus antibody
10. Body Mass Index (BMI) 19.0 to 32 kg/m
11. Cold pressor screening results as follows: 1) pain tolerance of > 20 seconds and <120 seconds

Exclusion Criteria:

1. Oral temperature > 38°C or history of current illness
2. History of seizures, epilepsy, or recognized increase risk of seizure (e.g., head trauma, metabolic disorders, alcohol or drug withdrawal)
3. History of cirrhosis or laboratory evidence of liver disease
4. Use of alcohol within 24 hours of day -1 until the end of the study; and grapefruit, grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), or grapefruit juice or grapefruit-related juices, or other medication, within 7 days of study drug administration and until the end of the study
5. History of previous anaphylaxis, severe allergic reaction to Tramadol, codeine, or other opioid drugs
6. Use of monoamine oxidase (MAO) inhibitors (including linezolid), Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and prescription or over-the counter (OTC) medications known to induce or inhibit drug metabolism, including cytochrome P450 2D6 (CYP2D6), and other drugs that may affect the serotonergic neurotransmitter systems including, but not limited to, triptans, dextromethorphan, tricyclic antidepressants, bupropion, lithium, tramadol, dietary supplements such as tryptophan and St. John's Wort, and antipsychotics or other dopamine antagonists. These restrictions are to be maintained from 14 days before study day -1, until the subject completes the study
7. Any other unstable acute or chronic disease that could interfere with the evaluation of the safety of the study drug as determined by the principal Investigator in dialogue with the Sponsor Medical Monitor
8. Unlikely to comply with the study protocol
9. Known or suspected alcohol or drug abuse within the past 6 months
10. Received another investigational agent within 4 weeks of Day 0, or within five half-lives of Day 0, whichever is longer; or receiving any other investigational agent during this study
11. Any concurrent disease or condition that in the opinion of the investigator impairs the subject's ability to complete the trial. Psychological, familial, sociological, geographical or medical conditions which, in the Investigator's opinion, could compromise compliance with the objectives and procedures of this protocol, or obscure interpretation of the trial data

Contacts and Locations

Locations

United States, Utah

CRI Lifetree Research Center

Salt Lake City, Utah, United States, 84106

Sponsors and Collaborators

Syntrix Biosystems, Inc.

National Institute on Drug Abuse (NIDA)

Investigators

• Principal Investigator: Shawn Searle, MD; PRA/CRI Lifetree Research Center
• Study Director: Stuart Kahn, MD; Syntrix Biosystems, Inc.

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zebala JA, Searle SL, Webster LR, Johnson MS, Schuler AD, Maeda DY, Kahn SJ. Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials. J Pain. 2019 Oct;20(10):1218-1235. doi: 10.1016/j.jpain.2019.04.005. Epub 2019 Apr 18.

• Responsible Party: Syntrix Biosystems, Inc.
• ClinicalTrials.gov Identifier: NCT02205554
• Other Study ID Numbers: Syntrix-Omni-Pain-101; R44DA027304 ( U.S. NIH Grant/Contract )
• First Posted: July 31, 2014
• Last Update Posted: October 15, 2014
• Last Verified: October 2014

Keywords provided by Syntrix Biosystems, Inc.:

Analgesia; Pharmacokinetics; Treatment

Additional relevant MeSH terms:

Tramadol; Analgesics, Opioid; Narcotics; Central Nervous System Depressants; Physiological Effects of Drugs; Analgesics; Sensory System Agents; Peripheral Nervous System Agents